MX2024010596A - Composiciones que comprenden 5-metoxi-2-aminoindano (meai) y n-aciletanolaminas y usos de las mismas - Google Patents

Composiciones que comprenden 5-metoxi-2-aminoindano (meai) y n-aciletanolaminas y usos de las mismas

Info

Publication number
MX2024010596A
MX2024010596A MX2024010596A MX2024010596A MX2024010596A MX 2024010596 A MX2024010596 A MX 2024010596A MX 2024010596 A MX2024010596 A MX 2024010596A MX 2024010596 A MX2024010596 A MX 2024010596A MX 2024010596 A MX2024010596 A MX 2024010596A
Authority
MX
Mexico
Prior art keywords
compositions
methoxy
acylethanolamines
meai
aminoindane
Prior art date
Application number
MX2024010596A
Other languages
English (en)
Spanish (es)
Inventor
Adi Zuloff-Shani
Original Assignee
Clearmind Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clearmind Medicine Inc filed Critical Clearmind Medicine Inc
Publication of MX2024010596A publication Critical patent/MX2024010596A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024010596A 2022-03-07 2024-08-29 Composiciones que comprenden 5-metoxi-2-aminoindano (meai) y n-aciletanolaminas y usos de las mismas MX2024010596A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263317257P 2022-03-07 2022-03-07
PCT/IB2023/052091 WO2023170552A1 (en) 2022-03-07 2023-03-06 Compositions comprising meai and n-acylethanolamines and uses thereof

Publications (1)

Publication Number Publication Date
MX2024010596A true MX2024010596A (es) 2025-01-09

Family

ID=85706794

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010596A MX2024010596A (es) 2022-03-07 2024-08-29 Composiciones que comprenden 5-metoxi-2-aminoindano (meai) y n-aciletanolaminas y usos de las mismas

Country Status (9)

Country Link
US (1) US20250302773A1 (https=)
EP (1) EP4489741A1 (https=)
JP (1) JP2025508052A (https=)
CN (1) CN119212690A (https=)
AU (1) AU2023231494A1 (https=)
CA (1) CA3244360A1 (https=)
IL (1) IL315486A (https=)
MX (1) MX2024010596A (https=)
WO (1) WO2023170552A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120225185A (zh) * 2022-09-21 2025-06-27 克力迈医药公司 5-甲氧基-2-氨基茚满(“meai”)在用于治疗代谢综合征的方法中的用途
WO2025196662A1 (en) * 2024-03-20 2025-09-25 Clearmind Labs Corp. Compositions and methods for treating eating disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US4818541A (en) 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
JP3342491B2 (ja) 1993-08-06 2002-11-11 ファルマシア・アンド・アップジョン・カンパニー 選択的ドーパミンｄ３リガンドとしての２−アミノインダン類
WO2005002524A2 (en) * 2003-07-02 2005-01-13 The Regents Of The University Of California COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES OF OLEOYLETHANOLAMIDE-LIKE COMPOUNDS AND MODULATORS OF PPARα
CN107406369B (zh) * 2014-12-09 2021-01-15 以西结·戈兰 放纵行为调节剂
ES2580508B1 (es) * 2016-04-11 2018-09-12 Servicio Andaluz De Salud Composiciones para la prevención y/o tratamiento de los trastornos por uso de alcohol.

Also Published As

Publication number Publication date
JP2025508052A (ja) 2025-03-21
CN119212690A (zh) 2024-12-27
EP4489741A1 (en) 2025-01-15
AU2023231494A1 (en) 2024-09-05
CA3244360A1 (en) 2023-09-14
US20250302773A1 (en) 2025-10-02
WO2023170552A1 (en) 2023-09-14
IL315486A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
MX2024010596A (es) Composiciones que comprenden 5-metoxi-2-aminoindano (meai) y n-aciletanolaminas y usos de las mismas
EP4506001A3 (en) SUBSTITUTED TETRAHYDROFURANS AS SODIUM CHANNEL MODULATORS
CR20220082A (es) N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
BR112017026159A2 (pt) inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
MX2020005518A (es) Mezclas no racemicas y usos de las mismas.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
AR117655A1 (es) Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal
MX2024000828A (es) Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.
SA523440574B1 (ar) مثبطات إنترليوكين-17
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
MX384072B (es) Compuesto derivado de pirrolo-piridina, metodo para preparar el mismo y composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o el tratamiento de enfermedades relacionadas con la proteina cinasa.
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
MX2022012001A (es) Tratamiento preventivo de la migra?a.
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
CL2023002698A1 (es) Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos
BR112022009881A2 (pt) Inibidores de caspase 6 e usos dos mesmos
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
MX2021009219A (es) Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria.
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
WO2019004788A3 (ko) 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.